Monoclonal antibody therapies that target epidermal growth factor receptor (EGFR), including cetuximab (Erbitux, ImClone, LLC) and panitumumab (Vectibix, Amgen), are becoming widely used approaches 2, particularly for patients with chemorefractory metastatic disease 3. The gene discussed is EGFR; the disease is metastatic neoplasm.